Please assess the completion status of the following clinical trial:

Trial Title: LAS41005 in Hyperkeratotic Actinic Keratosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Signed and dated written informed consent.~* Men and women aged between 18 and 85 years inclusive.~* Have a general good and stable health condition as confirmed by a physical examination and by medical history.~* Have at least 4 but not more than 10 clinically confirmed hyperkeratotic AK target lesions of moderate to severe intensity within the face/forehead or bald scalp~* Skin type I to IV according to Fitzpatrick's .~* Are free of any significant physical abnormalities (e.g., tattoos, dermatoses) in the potential treatment area that may cause difficulty with examination or final evaluation.~* Physical ability to apply the study preparation correctly and to follow the study restrictions and visit.~* Women of childbearing potential are allowed to participate in this study, only if they use a highly effective method of contraception~Main Exclusion Criteria:~* Have received treatment of AK within the treatment area (face / scalp) in the three months preceding this clinical trial.~* Have known hypersensitivity to the ingredients~* Are subjects under immunosuppressive therapy.~* Having coagulation defects which are inherited or acquired~* Have evidence of clinically significant, unstable medical conditions~* Have currently other malignant or benign tumors of the skin within the treatment area~* Subjects who have taken topical or systemic treatments that might interfere with the study end points, within a time window that is not allowed, or who are currently taking phenytoin, methotrexate or sulfonylurea.~* Subjects taking inhibitors of DPD (e.g. Brivudin, Sorivudin)~* Are known to be pregnant or lactating (currently or within the past 3 months).~* Have any dermatological disease in the treatment area or surrounding area that may be exacerbated by treatment~* Are currently or within the past 8 weeks participating in another clinical study.~* Have active chemical dependency or alcoholism as assessed by the investigator.~* Subject is institutionalized because of legal or regulatory order.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Drug Las41005
- 2 (Type: OTHER): Cryotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).